|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Microcatheter Imaging Technologies for Glaucoma Surgery |
|
| Management |
| Mike Nash, Co-founder; Ernie Edwards, Vice-President; Jerry Wroblewski, Sr. Vice President; Mark Hayward, Global Vice President of Sales; Ron Yamamoto, Chief Scientific Officer and Director; Stan Conston, co-founder; Matt Franklin, Chief Financial Officer
|
| |
|
|
| |
|
| Keywords |
| Microcatheter, Ophthalmologists, eye, Interventional Ophthalmology, Posterior Segment Access Technology, Anterior Segment Access Technology |
|
|
|
| Description |
|
iScience Interventional discovers and develops microcatheter and imaging technologies that enable ophthalmologists to deliver site-specific therapies in the anterior and posterior segments of the eye. The company is focused on advancing the use of canaloplasty, a microcatheter-based procedure that safely reduces intraocular pressure (IOP) and dependence on medications in open-angle glaucoma patients.
|
|
| Products / Services |
The iTrack 250A is a composite, multi-element canaloplasty microcatheter designed specifically to access small sensitive spaces within the eye. Its illuminated, atraumatic beacon tip is designed to allow exceptional visibility and trackability while minimizing the potential for tissue damage. iLumin is a laser-diode based, microillumination system that provides transscleral visualization of the iTrack microcatheter beacon tip. It also provides direct visualization of the microcatheter location within the ocular anatomy, optimizing surgeon control. The iUltraSound is a high-definition imaging system that provides enhanced visualization of key ocular outflow structures in the anterior segment. iUltraSound provides an accurate morphological assessment of surgically created drainage passageways, along with natural drainage structures such as Schlemm's canal and aqueous collector channels. The iUltraSound system is uniquely designed for in-office or intraoperative imaging for glaucoma management.
|
|
| Technology / Differentiation |
| iScience has pioneered a subspecialty known as Interventional Ophthalmology, founded on the use of microcatheter and guidance technologies to deliver site-specific therapies via physiological routes of access. It encompasses procedures such as: Anterior Segment Access Technology (ASAT), a microcatheter-based therapy designed to access a wide range of anatomical structures within the anterior segment of the eye; and Posterior Segment Access Technology (PSAT), a method of aspirating ocular fluids or delivering sterile ophthalmic solutions to specific targets in the back of the eye. Prior to the advent of Interventional Ophthalmology, many anterior and posterior segment diseases had been sub-optimally addressed due to the inability of existing technologies to provide site-specific treatment. The procedural component of Interventional Ophthalmology is referred to as an iCath procedure, which uses the iTrack microcatheter to deliver site-specific ocular therapies. |
|
| Market / Customers |
Glaucoma is a sight-threatening eye disease affecting an estimated 4 million Americans; only half of these individuals have been formally diagnosed with the condition. Primary Open Angle Glaucoma (POAG) is the most common form of glaucoma, occurring in approximately 90% of all glaucoma patients. In terms of Social Security benefits, lost income tax revenues, and health care expenditures, glaucoma costs the U.S. over $1.5 billion annually.
|
|
| Status |
| In August 2008, the company's products received expanded 510(k) indications for use from the FDA for specific treatment of primary open angle glaucoma (POAG).
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members